Study guide

4.1 Whole Blood & Red Blood Cells

Specialist in Blood Banking, SBB ASCP

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility Routes & Credential Maintenance 1.3 Study Strategy for SBB

2 Donors & Collection

2.1 Donor Qualification 2.2 Collection Methods & Adverse Reactions 2.3 Special Donations

3 Processing, Storage & Component QC

3.1 Processing, Testing & Labeling 3.2 Storage, Transport & Expiration 3.3 Blood Component Quality Control

4 Red Cell & Modified Components

4.1 Whole Blood & Red Blood Cells 4.2 Leukocyte-Reduced, Washed, Frozen & Rejuvenated RBCs 4.3 Irradiated Components 4.4 Granulocytes

5 Platelets, Plasma & Cellular Products

5.1 Platelets 5.2 Plasma & Cryoprecipitated AHF 5.3 Apheresis Products & Fractionation Products 5.4 Hematopoietic Progenitors

6 Genetics, ABO & Rh

6.1 Blood Group Genetics & Molecular Inheritance 6.2 ABO & Lewis Systems 6.3 Rh System 6.4 MNS, P1PK/Globoside & Ii

7 Other Blood Groups & Role in Transfusion

7.1 Kell, Kidd, Duffy & Lutheran 7.2 Other Systems & High/Low-Prevalence Antigens 7.3 HLA, Platelet-Specific & Granulocyte Antigens 7.4 Immunogenicity & Antigen Prevalence

8 Immunology Foundations

8.1 Immune Response 8.2 Immunoglobulins 8.3 Antigen-Antibody Interactions 8.4 Complement

9 Physiology, Hemostasis & HDFN

9.1 Physiology of Blood 9.2 Hemostasis and Coagulation 9.3 HDFN Pathophysiology & Detection 9.4 HDFN Treatment & Prevention

10 Cytopenias & Transplantation

10.1 Immune & Nonimmune Anemia 10.2 Thrombocytopenia & Neutropenia 10.3 Solid Organ Transplantation Support 10.4 Hematopoietic Progenitor Cell Transplantation

11 Routine Serologic Testing

11.1 Blood Grouping Tests 11.2 Antibody Detection & Crossmatch 11.3 Antibody Identification & Clinical Significance 11.4 Direct Antiglobulin Testing & Reagents

12 Special Serologic Methods

12.1 Enzymes, Enhancement Media & Lectins 12.2 Adsorptions, Elutions & Titrations 12.3 Cell Separations, Neutralization & Thiol Reagents 12.4 Chloroquine Diphosphate & EDTA-Glycine Acid

13 Molecular Platforms & Serologic QA

13.1 Molecular Blood Group Techniques 13.2 ELISA, Immunofluorescence, Solid Phase & Column Agglutination 13.3 Serologic Quality Assurance

14 Indications, Component Therapy & PBM

14.1 Indications for Transfusion 14.2 Component Therapy 14.3 Blood Administration & Patient Blood Management

15 Adverse Effects of Transfusion

15.1 Immunologic Transfusion Reactions 15.2 Nonimmunologic Reactions 15.3 Transfusion-Transmitted Diseases

16 Apheresis & Extracorporeal Circulation

16.1 Therapeutic Apheresis 16.2 Extracorporeal Circulation

17 Quality, Safety, Math & Instrumentation

17.1 Quality Assessment & Troubleshooting 17.2 Laboratory Safety 17.3 Laboratory Mathematics 17.4 Instrumentation

18 Laboratory Administration (SBB Only)

18.1 Financial Management 18.2 Operations & Information Technology 18.3 Personnel, Education & Training 18.4 Quality Management, Risk & Tissue Management

4.1 Whole Blood & Red Blood Cells

Key Takeaways Explain This Topic AI

A unit of Whole Blood is 450-500 mL (±10%) of blood collected with anticoagulant, and in the U.S. it is almost always separated into components; modern transfusable Whole Blood use is limited to neonatal exchange transfusion, low-titer group O whole blood (LTOWB) trauma resuscitation, and select pediatric cardiac surgery priming.

CPD and CP2D support 21-day storage, CPDA-1 (adenine-containing) extends storage to 35 days, and FDA-approved additive solutions (AS-1, AS-3, AS-5, AS-7) extend storage to 42 days while lowering final hematocrit to about 55-65%, versus 70-80% for non-additive units.

One unit of Red Blood Cells raises an average 70 kg adult's hemoglobin by about 1 g/dL (hematocrit by about 3%); a smaller rise suggests active bleeding, hemolysis, or sequestration rather than a dosing error.

The RBC storage lesion includes falling 2,3-DPG and ATP, rising extracellular potassium and free hemoglobin, and falling pH; large randomized trials (ABLE, RECESS, INFORM) found no outcome benefit to using fresher blood over standard-aged units within the approved storage window.

Last updated: July 2026

Whole Blood: A Legacy Component With Narrow Modern Indications

Whole Blood (WB) is a single unit of blood collected directly from a donor into a bag containing an anticoagulant-preservative solution, with no component separation performed. A standard collection is 450 mL or 500 mL of blood (±10%) drawn into a proportional volume of anticoagulant. Because nearly all whole blood collected in the U.S. is separated into components (Red Blood Cells, plasma, and platelets/cryoprecipitate) within hours of collection to maximize the clinical yield of a single donation, transfusable Whole Blood is now a minor, specialized product rather than a routine inventory item.

Modern indications for Whole Blood are narrow and specific: (1) exchange transfusion in neonates, (2) massive hemorrhage and exsanguinating trauma in settings (military, rural, or civilian trauma centers using low-titer group O whole blood, or LTOWB) where rapid balanced resuscitation is logistically difficult with separated components, and (3) cardiopulmonary bypass priming in some pediatric cardiac surgery programs. LTOWB programs screen group O donors for low anti-A/anti-B titers (commonly below 256) to allow use in non-group-O recipients without a formal crossmatch delay, reflecting a resurgence of interest in Whole Blood for trauma resuscitation.

Anticoagulant-Preservative Solutions and Storage Duration

The anticoagulant-preservative solution chosen at collection determines both red cell storage duration and metabolic quality. The SBB must know each formulation and its consequences cold.

  • Solution Key Additives RBC Storage (1-6°C) Notes
  • ACD (Acid-Citrate-Dextrose) Citrate, dextrose 21 days Largely historical; low pH

CPD (Citrate-Phosphate-Dextrose) Citrate, phosphate, dextrose 21 days Phosphate buffers pH, better ATP maintenance than ACD

CP2D Citrate, phosphate, double dextrose 21 days Higher dextrose supports glycolysis

CPDA-1 (CPD-Adenine) Citrate, phosphate, dextrose, adenine 35 days Adenine is an ATP precursor, extending storage 14 days beyond CPD

Additive solutions (AS-1, AS-3, AS-5, AS-7) Saline, adenine, glucose/dextrose, mannitol (AS-1/AS-5) or phosphate (AS-3) 42 days Added after plasma removal, to the packed cell mass, not at collection

Units collected in CPD, CP2D, or CPDA-1 without an additive solution retain a hematocrit of roughly 70-80% , because all of the original plasma volume beyond what is needed for anticoagulation has been removed with minimal replacement fluid. Once an additive solution (about 100 mL) is added to the packed cells after plasma and/or platelet-rich plasma removal, the hematocrit drops to approximately 55-65% , producing a less viscous, more easily transfused unit — a major reason additive solutions became the U.S. standard.

Preparing Red Blood Cells

Red Blood Cells (RBCs) are the component remaining after centrifugation removes most of the plasma (and, if the facility separates platelets, the platelet-rich or platelet-poor plasma layer) from a Whole Blood collection. A single unit contains approximately 200 mL of red cells, with a final volume of 300-400 mL once resuspended in additive solution, and it must be stored continuously at 1-6°C. RBCs are the mainstay product for correcting symptomatic anemia and are far more commonly transfused than Whole Blood.

Dosing rule of thumb: one unit of RBCs in a 70 kg adult raises hemoglobin (Hb) by approximately 1 g/dL (or hematocrit by roughly 3%), assuming no ongoing loss. A patient with active bleeding or hemolysis will show a smaller-than-expected increment, which the SBB should recognize as a clinical clue rather than a laboratory error.

The Storage Lesion

During refrigerated liquid storage, RBCs undergo a well-characterized set of biochemical changes collectively called the storage lesion . The SBB exam tests both the mechanism and the clinical consequence of each change.

Falling 2,3-diphosphoglycerate (2,3-DPG): 2,3-DPG stabilizes deoxyhemoglobin and shifts the oxyhemoglobin dissociation curve to the right, favoring oxygen release to tissue. As 2,3-DPG falls during storage (to under 10% of normal by roughly two weeks in non-rejuvenated units), the curve shifts left, and transfused cells temporarily bind oxygen more tightly and release it less readily. 2,3-DPG regenerates in vivo within 24-72 hours post-transfusion, so the clinical effect is transient but relevant in massive or rapid transfusion of critically ill patients.

Falling adenosine triphosphate (ATP): ATP is required for red cell membrane deformability and shape maintenance. As ATP depletes, cells transition from smooth discocytes to crenated echinocytes, and post-transfusion in vivo recovery declines — this is the biochemical basis for the FDA/AABB minimum 75% 24-hour post-transfusion recovery requirement used to validate maximum storage durations.

Rising extracellular potassium: As the sodium-potassium ATPase pump slows (less ATP available) and cell membranes leak, intracellular potassium exits into the supernatant plasma or additive solution, accumulating over storage. This matters clinically for rapid, large-volume transfusion into neonates or renally compromised patients, and it is the reason irradiated units — which leak potassium faster — carry a shortened outdate, covered later in this chapter.

Rising free plasma hemoglobin and microparticles: Ongoing low-level hemolysis releases free hemoglobin and generates red cell-derived microparticles, both of which increase with storage age and are markers of storage lesion severity.

Falling pH: Continued glycolysis produces lactic acid, and pH falls progressively, further slowing glycolysis in a self-limiting cycle — this is why phosphate-buffered CPD outperformed ACD, and why adenine in CPDA-1 extends usable storage by keeping ATP synthesis running longer.

Applying This to Practice

An SBB candidate should recognize that day-30 versus day-5 RBC units differ biochemically, but current evidence has not shown a clinically meaningful outcome difference between fresher and older units within the approved storage window for most patient populations — a key point after several large randomized trials (ABLE, RECESS, INFORM) failed to show benefit from fresher blood. The SBB should not confuse the existence of a storage lesion with an assumption that fresher blood improves outcomes; the exam frequently tests this distinction.